https://www.chamfondbiotech.com/4-types-of-bone-marrow-biopsy-needles/

Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation, is currently an important method for curing many malignant blood diseases, genetic disorders, and autoimmune diseases. However, not all patients are suitable for transplantation, and the success of the transplantation also depends on a series of complex preoperative evaluations. During this process, the bone marrow biopsy needle plays the role of a "passport," and its result directly determines whether the patient can embark on the transplantation journey and how to plan the best transplantation plan.

Initial Assessment

Firstly, bone marrow biopsy needles are the gold standard for assessing the initial condition of the patient. Before planning for transplantation, doctors must ensure that the patient's primary disease is controlled to the greatest extent possible. For example, for patients with acute leukemia, the ideal time for transplantation is during the first complete remission period (CR1). At this time, by obtaining samples through the bone marrow biopsy needle and conducting pathological and flow cytometry analyses, it is possible to confirm that the proportion of primitive cells in the bone marrow has dropped to a safe level (typically <5%), and there are no MRD positives. If the biopsy results show that the disease is not in remission or is in a refractory state, the risk of post-transplantation recurrence is extremely high. The doctor may recommend bridging chemotherapy or targeted therapy first, and then perform transplantation after achieving remission. Therefore, the results of the bone marrow biopsy are the key to determining whether the "entrance ticket" for transplantation is valid.

Bone Marrow Reserve Function

Secondly, the bone marrow biopsy needle is used to assess the bone marrow reserve function and microenvironment health status of the patient. The essence of transplantation is to introduce healthy hematopoietic stem cells into the recipient's body, allowing them to "take root and grow" in the recipient's bone marrow cavity. If the recipient's bone marrow is severely fibrotic, necrotic, or has impaired hematopoietic function due to previous multiple chemotherapy, radiotherapy, or the original disease itself, then the transplanted stem cells will have difficulty implanting. Through bone marrow biopsy, pathologists can evaluate the cell density of the bone marrow, the proportion of adipocytes, the content of reticular fibers, and the distribution of blood vessels. For example, if the biopsy shows extensive fibrosis of the bone marrow (such as primary myelofibrosis), it will affect the homing and proliferation of the stem cells, and the success rate of transplantation will significantly decrease. It may be necessary to adjust the intensity of the pre-treatment regimen or choose a different source of stem cells.

Non-Malignant Diseases

Furthermore, for non-malignant diseases such as severe aplastic anemia (SAA) or thalassemia, bone marrow biopsy needles are also a core tool for pre-transplant assessment. In SAA patients, bone marrow biopsy can make a definitive diagnosis and rule out other diseases that cause pancytopenia (such as hypoplastic MDS). The extremely empty and fatty appearance of the bone marrow shown by the biopsy is a typical feature of SAA and a strong indication for initiating transplantation treatment. For patients with thalassemia, pre-transplant bone marrow biopsy can assess the severity of erythroid ineffective hematopoiesis and iron overload, which is crucial for formulating individualized pre-treatment plans and post-treatment management.

Donor Assessment

Finally, the bone marrow biopsy needle is also used to find suitable donors or to assess the quality of the stem cells for autologous transplantation. In autologous transplantation, the patient's own hematopoietic stem cells are collected and cryopreserved, and then reinfused after high-dose chemotherapy. Before collection, it is crucial to confirm through bone marrow biopsy that there is no contamination of tumor cells in the patient's bone marrow. If residual tumor cells are found in the biopsy, the mobilization protocol needs to be adjusted or in vitro purification techniques need to be considered. Additionally, in allogeneic transplantation, donors (especially monozygotic twins or siblings) sometimes also need to undergo bone marrow biopsy to confirm the health of their bone marrow and ensure it is suitable for donation.

Conclusion

In summary, the bone marrow biopsy needle plays the role of a "gatekeeper" throughout the entire process of hematopoietic stem cell transplantation. It not only determines whether a patient is eligible for the transplantation, but also provides indispensable biological evidence for the personalized design of the transplantation plan, and is an important bridge connecting diagnosis and cure.